Nucryst Pharmaceuticals appoints director

May 31, 2006 — Nucryst Pharmaceuticals (NASDAQ: NCST) announced that it has appointed David Poorvin to its board of directors.

Poorvin has more than 30 years experience in the pharmaceutical industry. He also serves as a consultant for Poorvin Enterprises, an executive-in-residence for Oxford Bioscience Partners, and is a member of the board of directors for Enanta Pharmaceuticals and Repros Therapeutics.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.